AuntMinnie reported on October 5, 2026 that PSMA-PET scans can be used to guide low-dose-rate (LDR) brachytherapy in prostate cancer. The outlet's coverage focuses on how the imaging approach informs this form of treatment.
A separate item from Cleveland Clinic states that PSMA PET scan-guided LDR brachytherapy can control recurrence in localized prostate cancer. That report describes the technique's role in managing disease that has returned in its early, localized stage.
The two reports point to a shared theme: PSMA-PET imaging is being applied not only to detect prostate cancer but to help direct how it is treated. LDR brachytherapy is a treatment in which radioactive material is placed inside the prostate, and the Cleveland Clinic item links the imaging method to control of local recurrence.
Related coverage in the same roundup shows broader movement around prostate cancer theranostics, an approach that pairs diagnosis and therapy. Canadian experts have released national guidance on prostate cancer theranostics, according to a PR Newswire item carried by the Chinook Observer. Separately, 6abc Philadelphia reported on how theranostics combines diagnostics and therapy for advanced prostate cancer treatment.
Taken together, the reports suggest growing clinical attention to pairing prostate-specific imaging with treatment decisions across different stages of the disease, from localized recurrence to advanced cases.
What to watch next: whether the Canadian national guidance and the Cleveland Clinic findings lead to wider adoption of PSMA-PET-guided brachytherapy planning.
